Victory Capital Management
RARE icon

Victory Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Victory Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$375K Sell
17,901
-2,006
-10% -$45.2K ﹤0.01% 2084
2025
Q4 		$458K Sell
19,907
-278,984
-93% -$9.17M ﹤0.01% 2046
2025
Q3 		$8.99M Sell
298,891
-116,842
-28% -$3.5M 0.01% 1139
2025
Q2 		$15.1M Buy
415,733
+405,303
+3,886% +$14.6M 0.01% 974
2025
Q1 		$378K Buy
10,430
+124
+1% +$5.16K ﹤0.01% 2085
2024
Q4 		$434K Sell
10,306
-642
-6% -$31.9K ﹤0.01% 2062
2024
Q3 		$608K Buy
10,948
+884
+9% +$45K ﹤0.01% 1958
2024
Q2 		$414K Sell
10,064
-95
-0.9% -$4.06K ﹤0.01% 2026
2024
Q1 		$474K Sell
10,159
-406
-4% -$19.2K ﹤0.01% 1996
2023
Q4 		$505K Buy
10,565
+3,259
+45% +$126K ﹤0.01% 1993
2023
Q3 		$260K Buy
7,306
+156
+2% +$6.18K ﹤0.01% 2155
2023
Q2 		$330K Sell
7,150
-167
-2% -$7.75K ﹤0.01% 2095
2023
Q1 		$293K Sell
7,317
-75
-1% -$3.22K ﹤0.01% 2149
2022
Q4 		$342K Sell
7,392
-3
-0% -$118 ﹤0.01% 2140
2022
Q3 		$306K Sell
7,395
-73
-1% -$3.75K ﹤0.01% 2240
2022
Q2 		$446K Buy
7,468
+9
+0.1% +$554 ﹤0.01% 2105
2022
Q1 		$527K Buy
7,459
+21
+0.3% +$1.46K ﹤0.01% 2110
2021
Q4 		$625K Buy
7,438
+823
+12% +$67K ﹤0.01% 2042
2021
Q3 		$597K Buy
6,615
+448
+7% +$40.5K ﹤0.01% 2080
2021
Q2 		$588K Sell
6,167
-250
-4% -$26K ﹤0.01% 2112
2021
Q1 		$731K Sell
6,417
-343
-5% -$46.7K ﹤0.01% 2041
2020
Q4 		$936K Buy
6,760
+2,040
+43% +$242K ﹤0.01% 1817
2020
Q3 		$388K Sell
4,720
-304
-6% -$25.2K ﹤0.01% 2054
2020
Q2 		$393K Sell
5,024
-5,606
-53% -$371K ﹤0.01% 2068
2020
Q1 		$472K Buy
10,630
+3,230
+44% +$168K ﹤0.01% 2112
2019
Q4 		$316K Buy
7,400
+1,087
+17% +$44.8K ﹤0.01% 2188
2019
Q3 		$270K Buy
+6,313
New +$343K ﹤0.01% 2111
2018
Q4 		– Sell
-510
Closed -$39K – 1809
2018
Q3 		$39K Buy
510
+67
+15% +$5.45K ﹤0.01% 1736
2018
Q2 		$34K Hold
443
– – ﹤0.01% 1777
2018
Q1 		$23K Hold
443
– – ﹤0.01% 1786
2017
Q4 		$21K Hold
443
– – ﹤0.01% 1784
2017
Q3 		$24K Hold
443
– – ﹤0.01% 1770
2017
Q2 		$28K Buy
443
+43
+11% +$2.59K ﹤0.01% 1761
2017
Q1 		$27K Buy
400
+78
+24% +$5.94K ﹤0.01% 1751
2016
Q4 		$23K Buy
322
+28
+10% +$1.99K ﹤0.01% 1749
2016
Q3 		$21K Buy
+294
New +$18.8K ﹤0.01% 1749

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Victory Capital Management's RARE Position: Q1 2026 in Review

Victory Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 10% in Q1 2026, selling an estimated $45.2K and leaving 17,901 shares worth $375K. The position accounts for ﹤0.01% of the portfolio, ranked #2084.

Victory Capital Management first reported a position in RARE in Q3 2016 and has held it in 36 quarters since. The position peaked at $15.1M in Q2 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Victory Capital Management held 17,901 shares of Ultragenyx Pharmaceutical worth $375K as of Q1 2026.
  • Victory Capital Management sold 2,006 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $45.2K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2084 holding.
  • Victory Capital Management first reported a position in Ultragenyx Pharmaceutical in Q3 2016 and has held it in 36 quarters since.
  • Victory Capital Management's Ultragenyx Pharmaceutical position peaked at $15.1M in Q2 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.